CN113041236A - 氟比洛芬巴布剂及其制备方法 - Google Patents
氟比洛芬巴布剂及其制备方法 Download PDFInfo
- Publication number
- CN113041236A CN113041236A CN202110308443.7A CN202110308443A CN113041236A CN 113041236 A CN113041236 A CN 113041236A CN 202110308443 A CN202110308443 A CN 202110308443A CN 113041236 A CN113041236 A CN 113041236A
- Authority
- CN
- China
- Prior art keywords
- flurbiprofen
- component
- cataplasm
- gas
- precipitation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 title claims abstract description 59
- 229960002390 flurbiprofen Drugs 0.000 title claims abstract description 59
- 238000002360 preparation method Methods 0.000 title abstract description 16
- 239000004094 surface-active agent Substances 0.000 claims abstract description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 22
- 238000002156 mixing Methods 0.000 claims abstract description 20
- -1 polybutylene Polymers 0.000 claims abstract description 20
- 239000000839 emulsion Substances 0.000 claims abstract description 16
- 229920001983 poloxamer Polymers 0.000 claims abstract description 12
- 101000656751 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 30S ribosomal protein S24e Proteins 0.000 claims abstract description 11
- 210000004400 mucous membrane Anatomy 0.000 claims abstract description 11
- 239000002904 solvent Substances 0.000 claims abstract description 11
- 239000000463 material Substances 0.000 claims abstract description 9
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 8
- 238000004132 cross linking Methods 0.000 claims abstract description 7
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 7
- 239000000945 filler Substances 0.000 claims abstract description 7
- 239000003906 humectant Substances 0.000 claims abstract description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 6
- 239000004584 polyacrylic acid Substances 0.000 claims abstract description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229960001631 carbomer Drugs 0.000 claims abstract description 3
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims abstract description 3
- 229920001748 polybutylene Polymers 0.000 claims abstract description 3
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims abstract description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract 2
- 238000003756 stirring Methods 0.000 claims description 60
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 33
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 19
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 19
- 108010010803 Gelatin Proteins 0.000 claims description 18
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 18
- 229920000159 gelatin Polymers 0.000 claims description 18
- 239000008273 gelatin Substances 0.000 claims description 18
- 235000019322 gelatine Nutrition 0.000 claims description 18
- 235000011852 gelatine desserts Nutrition 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 18
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 16
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 15
- 239000011975 tartaric acid Substances 0.000 claims description 15
- 235000002906 tartaric acid Nutrition 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 13
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 235000011187 glycerol Nutrition 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 239000002202 Polyethylene glycol Substances 0.000 claims description 10
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 10
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 10
- 239000000084 colloidal system Substances 0.000 claims description 10
- 238000001816 cooling Methods 0.000 claims description 10
- 229940124274 edetate disodium Drugs 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims description 10
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 10
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 10
- 239000004408 titanium dioxide Substances 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 8
- 239000000741 silica gel Substances 0.000 claims description 8
- 239000000499 gel Substances 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000004359 castor oil Substances 0.000 claims description 6
- 235000019438 castor oil Nutrition 0.000 claims description 6
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 6
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 claims description 5
- 229960003338 crotamiton Drugs 0.000 claims description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 4
- 229910052782 aluminium Inorganic materials 0.000 claims description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 claims description 4
- 239000001630 malic acid Substances 0.000 claims description 4
- 235000011090 malic acid Nutrition 0.000 claims description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 239000005995 Aluminium silicate Substances 0.000 claims description 3
- BWZOPYPOZJBVLQ-UHFFFAOYSA-K aluminium glycinate Chemical compound O[Al+]O.NCC([O-])=O BWZOPYPOZJBVLQ-UHFFFAOYSA-K 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 235000012211 aluminium silicate Nutrition 0.000 claims description 3
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- JGUXSUJNBHSZSR-PREAGGAWSA-H [Al+3].[Al+3].[O-]C(=O)[C@@H](N)CCC([O-])=O.[O-]C(=O)[C@@H](N)CCC([O-])=O.[O-]C(=O)[C@@H](N)CCC([O-])=O Chemical compound [Al+3].[Al+3].[O-]C(=O)[C@@H](N)CCC([O-])=O.[O-]C(=O)[C@@H](N)CCC([O-])=O.[O-]C(=O)[C@@H](N)CCC([O-])=O JGUXSUJNBHSZSR-PREAGGAWSA-H 0.000 claims description 2
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000000440 bentonite Substances 0.000 claims description 2
- 229910000278 bentonite Inorganic materials 0.000 claims description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 2
- 239000000920 calcium hydroxide Substances 0.000 claims description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 2
- 239000000174 gluconic acid Substances 0.000 claims description 2
- 235000012208 gluconic acid Nutrition 0.000 claims description 2
- 125000005456 glyceride group Chemical group 0.000 claims description 2
- 229940057995 liquid paraffin Drugs 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 2
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims description 2
- 229920001083 polybutene Polymers 0.000 claims description 2
- 229920001451 polypropylene glycol Polymers 0.000 claims description 2
- 229910021487 silica fume Inorganic materials 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 229960002920 sorbitol Drugs 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- 239000011787 zinc oxide Substances 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- 229920002472 Starch Polymers 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940015826 dihydroxyaluminum aminoacetate Drugs 0.000 claims 1
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 claims 1
- HSFQBFMEWSTNOW-UHFFFAOYSA-N sodium;carbanide Chemical group [CH3-].[Na+] HSFQBFMEWSTNOW-UHFFFAOYSA-N 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 238000001556 precipitation Methods 0.000 abstract description 92
- 239000003814 drug Substances 0.000 abstract description 30
- 229940079593 drug Drugs 0.000 abstract description 16
- 239000013078 crystal Substances 0.000 abstract description 13
- 238000003860 storage Methods 0.000 abstract description 11
- 238000010521 absorption reaction Methods 0.000 abstract description 7
- 230000007774 longterm Effects 0.000 abstract description 7
- 230000000052 comparative effect Effects 0.000 description 28
- 239000002674 ointment Substances 0.000 description 26
- 238000000576 coating method Methods 0.000 description 16
- 210000004379 membrane Anatomy 0.000 description 16
- 239000012528 membrane Substances 0.000 description 16
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 238000004806 packaging method and process Methods 0.000 description 9
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 8
- 239000007764 o/w emulsion Substances 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 230000035699 permeability Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000001186 cumulative effect Effects 0.000 description 5
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 229940075507 glyceryl monostearate Drugs 0.000 description 4
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 239000001433 sodium tartrate Substances 0.000 description 3
- 229960002167 sodium tartrate Drugs 0.000 description 3
- 235000011004 sodium tartrates Nutrition 0.000 description 3
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- 229940114069 12-hydroxystearate Drugs 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920002593 Polyethylene Glycol 800 Polymers 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
取样时间 | 0月 | 1月 | 2月 | 3月 | 6月 |
实施例1 | 无析出 | 无析出 | 无析出 | 无析出 | 无析出 |
实施例2 | 无析出 | 无析出 | 无析出 | 无析出 | 无析出 |
实施例3 | 无析出 | 无析出 | 无析出 | 无析出 | 无析出 |
实施例4 | 无析出 | 无析出 | 无析出 | 无析出 | 无析出 |
对比例1 | 无析出 | 析出 | 析出 | 析出 | 析出 |
对比例2 | 无析出 | 无析出 | 析出 | 析出 | 析出 |
对比例3 | 无析出 | 析出 | 析出 | 析出 | 析出 |
对比例4 | 无析出 | 无析出 | 无析出 | 析出 | 析出 |
取样时间 | 0月 | 1月 | 3月 | 6月 | 12月 |
实施例1 | 无析出 | 无析出 | 无析出 | 无析出 | 无析出 |
实施例2 | 无析出 | 无析出 | 无析出 | 无析出 | 无析出 |
实施例3 | 无析出 | 无析出 | 无析出 | 无析出 | 无析出 |
实施例4 | 无析出 | 无析出 | 无析出 | 无析出 | 无析出 |
对比例1 | 无析出 | 析出 | 析出 | 析出 | 析出 |
对比例2 | 无析出 | 无析出 | 析出 | 析出 | 析出 |
对比例3 | 无析出 | 无析出 | 析出 | 析出 | 析出 |
对比例4 | 无析出 | 无析出 | 无析出 | 析出 | 析出 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110308443.7A CN113041236B (zh) | 2021-03-23 | 2021-03-23 | 氟比洛芬巴布剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110308443.7A CN113041236B (zh) | 2021-03-23 | 2021-03-23 | 氟比洛芬巴布剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113041236A true CN113041236A (zh) | 2021-06-29 |
CN113041236B CN113041236B (zh) | 2023-03-10 |
Family
ID=76514474
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110308443.7A Active CN113041236B (zh) | 2021-03-23 | 2021-03-23 | 氟比洛芬巴布剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113041236B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114796100A (zh) * | 2022-03-04 | 2022-07-29 | 中山大学 | 一种吡罗昔康凝胶贴膏剂及其制备方法 |
CN115475152A (zh) * | 2022-11-09 | 2022-12-16 | 北京泰德制药股份有限公司 | 氟比洛芬的外用制剂及其制备方法 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07309749A (ja) * | 1994-05-19 | 1995-11-28 | Terumo Corp | フルルビプロフェン含有外用剤 |
CN1496743A (zh) * | 1993-07-08 | 2004-05-19 | ��˹��ŵ�� | 在载体组合物中加溶难溶于水的活性成分的药物组合物及其制法 |
CN104546803A (zh) * | 2013-10-24 | 2015-04-29 | 和心医药科技(上海)有限公司 | 一种氟比洛芬水凝胶贴膏及其组合物 |
CN106692052A (zh) * | 2015-11-13 | 2017-05-24 | 天津金耀集团有限公司 | 一种环孢素眼用乳剂组合物 |
JP2017178895A (ja) * | 2016-03-31 | 2017-10-05 | 三笠製薬株式会社 | フルルビプロフェン含有含水系貼付剤 |
CN107951864A (zh) * | 2017-12-04 | 2018-04-24 | 北京茗泽中和药物研究有限公司 | 氟比洛芬巴布剂 |
WO2019143114A1 (ko) * | 2018-01-18 | 2019-07-25 | 대화제약 주식회사 | 하이드로겔 패치 형태의 경피투여용 약학 조성물 |
CN110787150A (zh) * | 2017-11-21 | 2020-02-14 | 北京泰德制药股份有限公司 | 一种含有氟比洛芬的皮肤外用制剂 |
-
2021
- 2021-03-23 CN CN202110308443.7A patent/CN113041236B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1496743A (zh) * | 1993-07-08 | 2004-05-19 | ��˹��ŵ�� | 在载体组合物中加溶难溶于水的活性成分的药物组合物及其制法 |
JPH07309749A (ja) * | 1994-05-19 | 1995-11-28 | Terumo Corp | フルルビプロフェン含有外用剤 |
CN104546803A (zh) * | 2013-10-24 | 2015-04-29 | 和心医药科技(上海)有限公司 | 一种氟比洛芬水凝胶贴膏及其组合物 |
CN106692052A (zh) * | 2015-11-13 | 2017-05-24 | 天津金耀集团有限公司 | 一种环孢素眼用乳剂组合物 |
JP2017178895A (ja) * | 2016-03-31 | 2017-10-05 | 三笠製薬株式会社 | フルルビプロフェン含有含水系貼付剤 |
CN110787150A (zh) * | 2017-11-21 | 2020-02-14 | 北京泰德制药股份有限公司 | 一种含有氟比洛芬的皮肤外用制剂 |
CN107951864A (zh) * | 2017-12-04 | 2018-04-24 | 北京茗泽中和药物研究有限公司 | 氟比洛芬巴布剂 |
WO2019143114A1 (ko) * | 2018-01-18 | 2019-07-25 | 대화제약 주식회사 | 하이드로겔 패치 형태의 경피투여용 약학 조성물 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114796100A (zh) * | 2022-03-04 | 2022-07-29 | 中山大学 | 一种吡罗昔康凝胶贴膏剂及其制备方法 |
CN114796100B (zh) * | 2022-03-04 | 2023-09-22 | 中山大学 | 一种吡罗昔康凝胶贴膏剂及其制备方法 |
CN115475152A (zh) * | 2022-11-09 | 2022-12-16 | 北京泰德制药股份有限公司 | 氟比洛芬的外用制剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN113041236B (zh) | 2023-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090136549A1 (en) | Transdermal patch containing rasagiline for treatment or prophylaxis of nervous system disease and its preparation process | |
NO20161918A1 (no) | Preparater for transdermal oksybutyninterapi | |
JPH03232817A (ja) | 貼付剤 | |
CN113041236B (zh) | 氟比洛芬巴布剂及其制备方法 | |
EP0666737A1 (en) | Transdermal delivery of the eutomer of a chiral drug | |
CN105997955B (zh) | 一种帕洛诺司琼口腔膜剂及其制备方法 | |
KR101727347B1 (ko) | 디클로페낙 나트륨 함유 수성 패치 | |
CN104546803A (zh) | 一种氟比洛芬水凝胶贴膏及其组合物 | |
CN110787150A (zh) | 一种含有氟比洛芬的皮肤外用制剂 | |
CN110719777A (zh) | 消炎镇痛外用剂 | |
US9861598B2 (en) | Ketoprofen lysine salt-containing aqueous patch | |
CN111825548B (zh) | 一种含有芳基丙酸类化合物的药物组合物 | |
Yamamura et al. | Oral mucosal adhesive film containing local anesthetics: in vitro and clinical evaluation | |
WO2021098791A1 (zh) | 一种含有美金刚的透皮贴剂 | |
CN101151028A (zh) | 局部用凝胶组合物 | |
CN114796100B (zh) | 一种吡罗昔康凝胶贴膏剂及其制备方法 | |
CN115475152A (zh) | 氟比洛芬的外用制剂及其制备方法 | |
CN104367566A (zh) | 一种吲哚美辛巴布剂及其组合物 | |
CN1989955B (zh) | 联苯乙酸巴布剂 | |
CN111803470B (zh) | 含有右酮洛芬或其药用盐的凝胶贴膏基质及其制备方法 | |
US20180177800A1 (en) | Composition for percutaneous absorption | |
CN107028915B (zh) | 含有布比卡因或其药用盐的皮肤外用制剂 | |
CN113069437A (zh) | 一种含有洛索洛芬及其药用盐的外用凝胶贴膏剂及其制备方法 | |
CN113194938A (zh) | 消炎镇痛外用剂 | |
JP2838297B2 (ja) | コルヒチン含有外用剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information |
Inventor after: Wu Chuanbin Inventor after: He Jian Inventor after: Liu Zhigang Inventor after: Chen Hangping Inventor after: Liu Chenhong Inventor after: Feng Rupeng Inventor after: Li Feng Inventor after: Wen Xinguo Inventor after: Zhang Minmin Inventor before: Wu Chuanbin Inventor before: Chen Hangping Inventor before: Liu Chenhong Inventor before: Feng Rupeng Inventor before: Li Feng Inventor before: Wen Xinguo Inventor before: Zhang Minmin |
|
CB03 | Change of inventor or designer information | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231207 Address after: No.1 Guanqing Road, Guanlan hi tech park, Guanhu street, Longhua District, Shenzhen, Guangdong Province Patentee after: CHINA RESOURCES SANJIU MEDICAL & PHARMACEUTICAL Co.,Ltd. Address before: 510006 Room 101, Department 1, Guangdong Pharmaceutical College, 280 Waihuan East Road, Xiaoguwei street, Panyu District, Guangzhou City, Guangdong Province Patentee before: NEWORLD PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right |